PBAC's latest decision on Cefuroxime axetil: Recommended (2015). Considered for Treatment of mild to moderately severe infections caused by sensitive bacteria, including tonsillitis, pharyngitis, and acute bacterial otitis media.
PBAC outcome
Recommended
Unrestricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2015
Submissions
1
2015 → 2015
Eligible population
Patients requiring treatment for mild to moderately severe infections caused by sensitive bacteria; specific subgroup consideration for paediatric patients 3 months to 12 years of age for the suspension formulation.
Therapy area
Infectious disease
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Economic model
BIA only
ICER note
Not modelled; minor submission (formulation and pack size change only).